Aspire Biopharma Holdings, Inc. announced that stockholders approved three proposals related to outstanding warrants at a Special Meeting held on June 16, 2026. The approvals authorize the company to issue common stock upon the exercise of these warrants and to adjust their terms, ensuring compliance with Nasdaq listing rules.
Key Details
- Warrant Issuance Approval: Stockholders authorized the issuance of common stock upon warrant exercise, including amounts that exceed 19.99% of outstanding shares, as required by Nasdaq Rule 5635(d).
- Exercise Price Adjustment: The proposals approved an aggregate exercise price of $0.00001 per share for the warrants and other voluntary adjustments to the exercise price.
- Financial Advisor Warrants: A proposal was also approved to adjust the number of common stock shares issuable upon the exercise of warrants held by the company's financial advisor.